Key Highlights
- Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) traded 29.68% higher at USD 13.57 in trading on November 5, 2026, per published market data, on Volume of 3 million shares.
- Third quarter 2026 Revenue rose 44% to USD 107.2 million from USD 74.4 million, with Recorlev up 93% to USD 71.5 million.
- Net income was USD 11.3 million against USD 0.6 million a year earlier, and adjusted EBITDA reached USD 30.8 million versus USD 17.4 million.
- Full-year 2026 revenue guidance was raised to USD 395 million to USD 405 million, and the 2030 outlook now exceeds USD 1 billion.
Results and Raised Outlook
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) released third quarter 2026 results on November 5, 2026, and the shares jumped in the same session. In trading on November 5, 2026, per published market data, the stock was quoted at USD 13.57, up 29.68%, with a Market Value near USD 2.47 billion. Total revenue was USD 107.2 million, up 44% from USD 74.4 million, and Net Income was USD 11.3 million compared with USD 0.6 million. The company lifted its 2026 revenue guidance to USD 395 million to USD 405 million and raised its 2030 total revenue outlook to more than USD 1 billion from about USD 750 million. Chairman and chief executive John Shannon said the company is now on a path to exceed USD 1 billion in 2030.
Product Mix and Balance Sheet
Recorlev, a treatment for Cushing's syndrome, generated USD 71.5 million, up 93%, and is now the main growth engine. Gvoke, the ready-to-use glucagon, fell 14% to USD 21.7 million, a decline that included a one-time gross-to-net adjustment of about USD 4 million, which is a revision to rebates and discounts that reduces reported sales. Keveyis rose 9% to USD 13.0 million. Adjusted EBITDA, which excludes interest, taxes, Depreciation and certain non-cash items, was USD 30.8 million. Over nine months revenue reached USD 282.5 million, up 37%, yet the net loss was USD 17.6 million because of a one-time non-cash charge of about USD 30.8 million tied to the 2028 convertible notes exchange. Cash was USD 131.1 million and long-term Debt was USD 189.7 million after the notes were retired on July 15, 2026.
Concentration and Execution Risks
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) now leans heavily on Recorlev, which produced about two-thirds of quarterly revenue on simple arithmetic, so any pricing, competition or reimbursement shift would weigh on results. The decline at Gvoke shows that not every product is growing. Long-term debt of USD 189.7 million remains meaningful against cash of USD 131.1 million, and published market data shows trailing Earnings of negative USD 0.10 per share, so the company is only recently profitable on a quarterly basis. A 2030 target above USD 1 billion is an ambition, not a forecast guaranteed by contracts, and a rally of this size can retrace. Investors should watch Recorlev prescription trends, Gvoke stabilization, debt reduction and the fourth quarter report.
Where Things Stand
The 29.68% surge at Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is tied to concrete news: revenue up 44%, a swing to USD 11.3 million of quarterly net income, higher 2026 guidance and a 2030 target above USD 1 billion. Those facts justify a strong reaction, though a jump of this size also prices in continued Recorlev growth. Debt, product concentration and the Gvoke decline are the main counterweights, and the nine-month net loss shows profitability is still new. The next catalysts are the fourth quarter report and any update to the long-term targets.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...